When Leuprolide (LHRHa) was given to female rats in twice-daily injections, the adrenal weight increased after 21 days of treatment, whereas administration by osmotic minipumps produced no significant effect on adrenal weight. When another agonist, Zoladex (LHRHz), was given continuously for 52 ...
The product is the only LHRH (luteinising hormone releasing hormone) agonist with the innovative, controlled-release ATRIGEL Delivery System. TOLMAR Pharmaceuticals receives FDA label update approval for ELIGARD prostate cancer drug This is also proven by the fact that treatment of hypothyroid infertile...
Dictionary Medical Wikipedia Related to LHRH:goserelin,LHRH agonist,LHRH analogue AcronymDefinition LHRHLuteinizing Hormone-Releasing Hormone(produced in hypothalamus) LHRHLuteotrophic Hormone-Releasing Hormone(neuroscience) LHRHLuteal Hormone Releasing Hormone ...
Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 g/kg of a potent LHRH agonist, nafarelin acetate, for 44 days. Although there was a rise in the circulating levels of the gonadotropins and of testosterone following the early injections of agonist, ...
Daily injections of an LHRH agonist, [D-Ala6, des-Gly-NH210]LHRH ethylamide (LHRH-A), 1 ug daily, for 38 days results in a 35% decrease in the number of tumors present at the beginning of the experiment compared to a decline of 45% after ovariectomy and of 8% in the control ...
Sharma, O.P. et al., "The Gonadotropin-Releasing Hormone (GnRH) Agonist-Induced Initial Rise of Bioactive LH and Testosterone can be Blunted in a Dose-Dependent Manner by GnRH Antagonist in the Non-Human Primate," Urological Research vol. 20, 317-321 (1992). ...
We hypothesized that patients on long term medical castration therapy would be willing to accept surgical castration as an alternative to repeated LHRH agonist injections.Methods:Men 鈮 18 years with metastatic PCa, on LHRH agonists for 鈮 1 year and 鈮 2 prior systemic therapies, were eligible....
8 patients with advanced prostatic carcinoma were treated with the luteinising-hormone releasing-hormone agonist, ICI 118630, for up to 3 months. Patients received subcutaneous injections of ICI 118630 (either 100 μg or 250 μg daily). At the higher dose level, plasma testosterone concentrations...
Patient Compliance in Treatment of Prostate Cancer with Luteinizing Hormone-Releasing Hormone (LHRH) Agonist,” Urology 42:533-535 - Shaheen, Amin, et al. - 1993Shaheen J., Amin M., Harty J. (1993) Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (...
Daily injections of an LHRH agonist, [D-Ala6, des-Gly-NH210]LHRH ethylamide (LHRH-A), 1 ug daily, for 38 days results in a 35% decrease in the number of tumors present at the beginning of the experiment compared to a decline of 45% after ovariectomy and of 8% in the control ...